Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 169.69M | 174.43M | 106.34M | 97.95M | 130.58M | 138.14M |
Gross Profit | 79.81M | 84.26M | 50.45M | 37.05M | 69.37M | 83.33M |
EBITDA | -116.89M | -118.14M | -54.46M | -173.57M | -43.77M | -34.60M |
Net Income | -132.76M | -138.88M | -74.66M | -190.10M | -59.24M | -53.02M |
Balance Sheet | ||||||
Total Assets | 579.60M | 612.34M | 323.07M | 390.31M | 275.21M | 324.76M |
Cash, Cash Equivalents and Short-Term Investments | 258.06M | 292.87M | 114.89M | 165.78M | 28.45M | 68.52M |
Total Debt | 31.53M | 33.00M | 98.21M | 102.66M | 111.65M | 95.38M |
Total Liabilities | 125.00M | 140.62M | 159.87M | 471.78M | 180.62M | 185.71M |
Stockholders Equity | 454.60M | 471.72M | 163.20M | -81.47M | 94.60M | 139.05M |
Cash Flow | ||||||
Free Cash Flow | -123.89M | -151.81M | -46.12M | -93.19M | -57.33M | -28.13M |
Operating Cash Flow | -111.26M | -143.45M | -43.29M | -89.37M | -44.06M | -15.42M |
Investing Cash Flow | 59.72M | 363.17M | 20.24M | -88.13M | -11.95M | 39.98M |
Financing Cash Flow | -82.93M | -102.62M | -6.81M | 230.76M | 15.96M | 20.86M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | $587.55M | 30.59 | -1.20% | ― | 38.43% | 86.19% | |
56 Neutral | $451.99M | ― | -25.73% | ― | 33.86% | 64.34% | |
55 Neutral | $581.18M | ― | -51.25% | ― | 15.57% | 31.82% | |
52 Neutral | $1.05B | ― | -3.04% | ― | -13.79% | 82.82% | |
51 Neutral | $599.13M | ― | -3.61% | ― | 1.71% | 76.00% | |
46 Neutral | C$190.36M | -4.25 | -8.56% | 3.09% | 13.53% | -1.76% | |
45 Neutral | $483.93M | ― | -13.84% | ― | 7.38% | 60.45% |
On June 22, 2025, Standard BioTools Inc. announced a strategic sale of its subsidiaries, including SomaLogic, to Illumina, Inc. for up to $425 million. This transaction aims to simplify Standard BioTools’ operations, achieve adjusted EBITDA break-even, and retain strategic upside through royalties and commercialization rights. The deal reflects improvements made to the business and aligns with the company’s focus on profitability and long-term value creation.
The most recent analyst rating on (LAB) stock is a Buy with a $2.75 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.
Standard BioTools Inc. held its 2025 Annual Meeting of Stockholders on June 18, 2025, where stockholders approved an amendment to the company’s Amended and Restated 2011 Equity Incentive Plan, increasing the number of shares of common stock reserved for issuance by 17,400,000 shares. Additionally, the election of Class III directors, approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm were also confirmed during the meeting.
The most recent analyst rating on (LAB) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.
Standard BioTools reported its financial results for the first quarter of 2025, showing a revenue of $40.8 million, a 10% decrease from the previous year. Despite the revenue decline, the company achieved a 45% reduction in operating loss and a 29% improvement in adjusted EBITDA, attributed to cost reductions and productivity gains. The company maintains a strong balance sheet with $261 million in cash and no material debt. The strategic focus on proteomics and the upcoming launch of a new NGS-based product are expected to drive future growth.